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Background: Scientiﬁc data provide the evidence that secondary K-RAS mutations do not occur during anti-
epidermal growth factor receptor therapy in colorectal cancer patients. This multicenter phase II prospective study aims
to investigate the activity of a retreatment with a cetuximab-based therapy.
Patients and methods: We enrolled 39 irinotecan-refractory patients who had a clinical beneﬁt after a line of
cetuximab- plus irinotecan-based therapy and then a progression of disease for which underwent a new line
chemotherapy and ﬁnally, after a clear new progression of disease, were retreated with the same cetuximab- plus
irinotecan-based therapy.
Results: Median number of therapeutic lines before accrual was 4. Median interval time between last cycle of ﬁrst
cetuximab-based therapy and ﬁrst cycle of the retreatment was 6 months. Overall response rate was 53.8% with 19
partial responses (48.7%) and 2 complete responses (5.1%). Disease stabilization was obtained in 35.9% of patients
and progression in four patients (10.2%). Median progression-free survival was 6.6 months. The correlation between
skin toxicity during ﬁrst cetuximab therapy and during cetuximab rechallenge was signiﬁcant (P = 0.01).
Conclusion: Rechallenge with the same cetuximab-based therapy may achieve a new important clinical beneﬁt further
delaying the progression of disease and improving the therapeutic options.
Key words: cetuximab, colorectal neoplasms, clinical trial, phase II, retreatment
introduction
Cetuximab (ERBITUX®) is a chimeric IgG1 monoclonal
antibody that bind extracellular domain of epidermal growth
factor receptor (EGFR) [1] preventing its linkage with
endogenous ligands such as transforming growth factor-α and
epidermal growth factor. Several phase II and phase III trials
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supported cetuximab combination in ﬁrst-line treatment of
metastatic colorectal cancer (mCRC) reporting a clinical
beneﬁt, progression-free survival (PFS), and overall response
rate (ORR) increase and higher rates of liver resections [2–5].
Other studies supported the use of cetuximab as a single agent
or in combination with irinotecan for patients who had
progressed on a previous chemotherapy [6–8]. The EGFR
activation leads to the activation of intracellular effectors
involved in intracellular signaling pathways, such as the G
protein K-ras.
Moreover, oncogene K-RAS mutations affect the clinical
response to anti-EGFR therapy. In fact, a large retrospective
analysis evaluated K-RAS mutation status in 113 patients
affected by irinotecan-refractory mCRC treated with cetuximab
or in combination with irinotecan in clinical trials. An ORR of
41% was observed in 27 of 66 patients with wild-type (WT) K-
RAS versus 0 of 42 in K-RAS-mutated patients. The median
overall survival was signiﬁcantly improved in patients with WT
K-RAS versus patients with mutated K-RAS (P = 0.02).
Decrease in tumor sizes was signiﬁcantly larger in WT K-RAS
patients [9]. Another prospective trial observed that patients
whose tumors do not have K-RAS mutations have a
signiﬁcantly higher disease control rate than patients with
K-RAS mutations (P = 0.0003) [10].
Then, other mutations downstream of EGFR could affect its
anti-EGFR effectiveness such as BRAF, Src [11, 12], and
PI3KCA. B-raf is a serine-threonine kinase and the principal
effector of K-ras. BRAF mutation (exons 15 and 21) in
colorectal cancer (CRC) occurs in a low percentage of cases
(5%–12% of cases) [13], but several studies have suggested that
it is associated with a decreased response to anti-EGFR therapy
[14–16].
PIK3CA is also commonly mutated in CRC (20% of cases)
[17]. It encodes the p110a subunit of PI3K regulating its
function. It has been associated with cetuximab resistance in
preclinical studies [18, 19]. Moreover, PI3KCA mutations have
been associated with panitumumab and cetuximab resistance
in retrospective analyses including patients affected by mCRC
[15]. Loss of phosphatase and tensin homolog protein, a
negative regulator of PI3K, has also been associated with
resistance to anti-EGFR therapy [20–22].
K-RAS mutation is an early pathogenic step in CRC
development, and it seems to remain the same during tumor
progression [23]. In fact, the same K-RAS mutations can be
detected in most adenoma and in more than a half of the
tumor adjacent mucosa [24]. One study analyzed K-RAS status
of CRC primary tumor and its metastasis sites in 21 patients. It
was observed that anti-EGFR therapy do not change K-RAS
status concordance between CRCs and corresponding
metastasis in 20 of 21 cases [25]. These data provided ﬁrst
evidence that secondary K-RAS mutations do not occur during
anti-EGFR therapy in CRC patients.
Basing on the hypothesis that K-RAS status remain the same
during the history of the disease, despite the treatments
received, we designed a phase II prospective study with the aim
of demonstrating that patients who responded and then
progressed during a cetuximab-based therapy can receive, after
a new line of therapy, a further line containing the same
cetuximab-based therapy gaining a clinical beneﬁt.
materials and methods
eligibility criteria
This is a multicentric phase II trial that examines irinotecan-refractory
patients who had a clinical beneﬁt [conﬁrmed stable disease (SD) for at
least 6 months or clinical response] after a line of cetuximab- plus
irinotecan-based therapy and then a progression of disease, during
cetuximab-based therapy, for which underwent a new line chemotherapy
and ﬁnally, after a clear new progression of disease, were retreated with the
same or another Cetuximab- plus Irinotecan-based therapy. Eligible
patients had histologic or cytologic conﬁrmation of CRC, with measurable
metastatic disease in at least one site identiﬁed by instrumental
examinations. All patients were required to be K-RAS WT (codons 12 and
13) with RT-PCR and K-RAS status was centrally assessed. Patients aged
between 40 and 80 years with an Eastern Cooperative Oncology Group
(ECOG) performance status one or less and a life expectance >3 months
were included. Bone marrow function requirements included an absolute
neutrophil count≥ 1500/mm3, a platelet count≥ 100 000/mm3 and
hemoglobin≥ 10.0 g/100 ml. Preserved renal function (serum creatinine≤
1.5 mg/dl and normal creatinine clearance), hepatic function (total
bilirubin≤ 1.5 mg/dl, aspartate aminotransferase and alanine
aminotransferase≤ 2.5 times normal). The study has been conducted in
accordance with the ethical principles that have their origin in the current
Declaration of Helsinki and all patients signed a written consent form prior
to the enrollment. Patients were excluded if adequate follow-up was not
possible (environmental or geographic difﬁculties, no compliance to
undergo necessary clinical-instrumental investigations, etc.).
treatment plan
Cetuximab was given at a loading dose of 400 mg/m2 followed by weekly
infusions of 250 mg/m2. Irinotecan was given at dose of 180 mg/m2 as a
90-min infusion day. A histamine-receptor antagonist and atropine (0.25
mg) were given as premedication before every infusion. Moreover,
dexamethasone was given at the dose of 20 mg before the induction course
and at the dose of 8 mg in the further courses. A standard antiemetic drug
was always given in the premedication and in the following days according
to the physician’s opinion. All the patients were to be treated until disease
progression or unacceptable toxic effects; no treatment holiday was
permitted. Tumor response was evaluated every 8 weeks with the use of
consistent imaging techniques [computed tomography (CT) or magnetic
resonance imaging]. The response to the treatment, both during cetuximab
treatment and rechallenge, prior or further treatments, was evaluated
centrally by two different radiologists and conﬁrmed by the investigators,
according to Response Evaluation Criteria in Solid Tumors (RECIST) [26].
toxicity and dose modiﬁcations
Toxic effects were assessed according to the National Cancer Institute—
Common Toxicity Criteria, 1998. Modiﬁcations of the dose of cetuximab
were carried out only in case of toxic effects to the skin not restoring after
2 weeks of rest, and modiﬁcations in the dose of irinotecan were made in
case of hematologic or non-hematologic toxic effects. Cumulative toxicity
was evaluated and recorded before each treatment cycle. Irinotecan
administration was stopped for more than or equal to G2 hematological
toxicity and was restarted in case of toxicity regression to G0–G1.
Reduction of 25% in Irinotecan dosing was applied for G3 non-
hematological toxicity and G4 hematological toxicity in the previous cycle.
The use of hemopoietic growth factors for white and red cell lines was
allowed when necessary.
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study schedule and evaluations
Screening assessments including medical history, physical examination
(including vital signs, height, weight, and Karnofsky Performance Scale
(KPS)), electrocardiogram (ECG), chest X-ray, and tumor measurements,
based on the appropriate imaging techniques (i.e. CT scan) or physical
examination, were conducted within 14 days before treatment initiation.
Laboratory data including complete blood count, blood chemistry, and
urinalysis were also obtained. During treatment, weekly assessments
included vital signs, physical measurements, KPS, complete blood counts,
and blood chemistry. For patients continuing treatment beyond 18 weeks,
these assessments were carried out at three-weekly intervals. Urinalysis,
chest X-ray, ECG, and brain CT scan were carried out if clinically
indicated. Patients could remain on treatment until disease progression
(evaluated with the best instrumental exams applicable in case of metastatic
lesions every 1 month of therapy) or the development of unacceptable
toxicity or patient’s refusal. All tumor measurements were reviewed and
conﬁrmed by an independent panel of radiologists and oncologists.
sample size and statistical considerations
The efﬁcacy analysis was based on the intent-to-treat population. The
primary end point was overall conﬁrmed response rate. The Simon
minimax two-stage design was used with early termination of the trial if a
predetermined minimum level of activity was not observed after the ﬁrst
stage of accrual. The sample size calculation was carried out to reject a 30%
response rate in favor of a target response rate of 50%, with a signiﬁcance
level of 0.05 and a statistical power of 80%. The preliminary activity of
cetuximab-based rechallenge was assessed through the accrual of 19
patients. If there were less than or equal to six responses, accrual needed to
be terminated. Otherwise 20 additional patients needed to be entered in the
second stage to achieve a target sample size of 39 evaluable patients for
tumor response. If >16 responses were observed in these 39 patients,
further assessment could be suggested. PFS was calculated from inclusion
date to progression documented or death date. Treated patients would have
been followed until disease progression. Safety was analyzed in all patients
who received at least one dose of study medication. SPSS software (version
11.05, SPSS, Chicago, IL) was used for statistical analysis.
results
patient characteristics
Demographic and other baseline characteristics of patient
population are summarized in Table 1. From February 2007 to
January 2010, a total of 39 patients were enrolled into the
study.
All patients, 11 females and 28 males, were assessable for
treatment efﬁcacy and safety. The median age of study
population was 59 years (range: 44–82 years), all patients had
an ECOG performance status of 0 or 1, and 71.2% had two or
more metastatic sites (28 patients) involving the liver (26
patients; 66.6%), the lung (14 patients; 35.9%), and the nodes
(17 patients; 43.6%). Primary tumor site was colon in the
48.7% of patients, rectosigmoid junction in the 28.2%, and
rectum in the 25.3% of patients. Median number of therapeutic
lines before study accrual, including original cetuximab
containing regimen, was 4 (3–7). All patients were irinotecan
refractory at the moment of the ﬁrst cetuximab-based therapy.
Chemotherapy protocols associated during ﬁrst cetuximab-
based therapy were the following: irinotecan monotherapy
(53.9%), FOLFIRI (46.1%). All the patients received a weekly
cetuximab schedule. Best responses after ﬁrst cetuximab-based
therapy: 6 complete responses (CRs), 29 partial responses
(PRs), and 4 SDs lasting at least 6 months. Median PFS with
ﬁrst treatment with cetuximab: 10 months (3–30) (Table 2).
The median interval time between last cycle of ﬁrst cetuximab-
based therapy and ﬁrst cycle of the following cetuximab
retreatment was 6 months (2–12). All patients have been
considered in progression at the moment of the study entry.
Chemotherapy protocols administrated after the ﬁrst
cetuximab-based therapy were the following: 5-ﬂuorouracil-
based therapy (17.9%), oxaliplatin-based therapy (51.3%);
Table 1 Patient characteristics
Characteristics No. of patients (%)
Total number 39 (100)
Male/female 28/11 (71/29)
Age (years)
Median 59
Range 44–82
Performance status
Median 0
Range 0–1
Primary tumor site
Colon 19 (49)
Rectum 9 (25)
Rectosigmoid 11 (29)
Tumor differentiation
Well differentiated 4 (10)
Moderately differentiated 15 (39)
Poorly differentiated or undifferentiated 20 (51)
Median number of metastatic sites (range) 2 (1–6)
1 11 (28)
2–3 18 (46)
>3 10 (26)
Sites of metastases
Liver 26 (67)
Lung 14 (36)
Nodes 17 (44)
Local 4 (10)
Other 8 (21)
Table 2 First cetuximab-based therapy: characteristics
Characteristics No. of patients
(%)
Total number 39 (100)
Irinotecan refractory 39 (100)
Protocol of association
Irinotecan monotherapy 21 (54)
FOLFIRI 18 (46)
Best response
Stable disease (>6 months) 4 (10)
Partial response 29 (74)
Complete response 6 (15)
Median time to progression—months (range) 10 (3–30)
Median number of lines before cetuximab retreatment
(range)
4 (3–7)
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irinotecan-based therapy (7.7%), oxaliplatin-based therapy
with bevacizumab (12.8%), and irinotecan-based therapy with
bevacizumab (2.6%), 5-ﬂuorouracil-based therapy with
bevacizumab (7.7%). Chemotherapy protocols associated
during cetuximab rechallenge-based therapy were the same
used during the ﬁrst cetuximab-based therapy: irinotecan in 21
patients (53.9%) and FOLFIRI in the remaining 18 patients
(46.1%).
antitumor efﬁcacy
All patients enrolled in the study were assessable for antitumor
efﬁcacy. In the ﬁrst stage of the study, six PRs and one CR
were obtained. For this reason, we proceed to the second stage
of the study. Considering all the included patients, the ORR
according to the International Rescue Committee assessment
was 53.8% [95% conﬁdence interval (CI) 39.1% to 63.7%] with
19 PRs (48.7%) and 2 CRs (5.1%). Disease stabilization was
obtained in 35.9% of patients (95% CI 24.7% to 51.6%) for a
clinical control rate of disease of 89.8%. Progression occurred
in only four patients (10.2%). The median PFS was 6.6 months
(95% CI 4.1% to 9.1%). Eighteen patients (46.1%) showed the
same type of response (SD, PR or CR) during cetuximab
retreatment when compared with the response obtained during
the ﬁrst cetuximab-based therapy, 2 patients (5.1%) has
increased the quality of clinical result, transiting from PR to
CR and from SD to PR, respectively (Table 3). Both, SD lasting
at least 6 months and PR during the ﬁrst cetuximab-based
therapy have been demonstrated to predict clinical beneﬁt after
cetuximab retreatment. The Kaplan–Meier curves for median
PFS are depicted in Figure 1.
safety results
All patients enrolled in the study were assessable for safety.
Most frequent grades 3–4 adverse events were skin rash and
diarrhea. Skin rash occurred in almost all patients (37 patients;
94.9%) and, as expected, it was generally moderate to severe in
intensity (grade 2: 41%; grade 3: 38.5%; no grade 4). It has
been demonstrated a signiﬁcant correlation between skin
toxicity during ﬁrst cetuximab therapy and cetuximab
rechallenge (P = 0.01). Diarrhea occurred in 22 (56.4%)
patients and was grades 3–4 in only 3 (7.7%) and grades 1–2 in
19 (48.7) patients. Seven (18%) patients developed grades 3–4
neutropenia and no one developed febrile neutropenia. Dose
delays were necessary in 17 patients (43.6%), mainly due to
skin toxicity. Cetuximab dose adjustment was made in 5
Figure 1. Kaplan–Meyer curve for progression-free survival. The median progression-free survival was 6.6 months [95% conﬁdence interval (CI) 4.1% to
9.1%].
Table 3 Clinical response after ﬁrst cetuximab-based therapy and second
cetuximab-based therapy in 39 patients
Best response 1st
cetuximab
Best response
rechallenge
No. of
patients
Total no.
(%)
PR CR 1 2 (5)
CR 1
SD PR 1 19 (49)
PR 14
CR 4
SD SD 3 14 (36)
PR 10
CR 1
PR PD 4 4 (10)
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(12.8%) patients because of skin toxicity. Six (15.4%) patients
required reduction of irinotecan dose, mainly because of
grade≥ 2 diarrhea. No patient was hospitalized due to toxic
effects and no toxic death or cardiac and thromboembolic
events occurred. Only two (5%) patients discontinued
treatment due to toxicity.
discussion
Data emerging from literature clearly pointed out that
activating mutations of K-RAS, BRAF, and PI3K predict lack of
response to cetuximab or panitumumab therapy [9, 27, 28].
Among these molecules, up to date, only K-RAS has been
validated for diagnostic applications, and the search for K-RAS
mutations in codons 12 and 13 of exon 2, described in 25% to
45% of patients, is today mandatory in order to establish the
best therapeutic option for mCRC patients. The presence of K-
RAS mutations in aberrant crypt foci [29] and in preneoplastic
lesions [30] suggests that these events occur at a very early
stage in human colorectal carcinogenesis. Moreover, despite
the different lines of therapy administered, the K-RAS gene
status seems to remain the same also in the advance phase of
the disease, as shown by the high concordance of K-RAS
testing results on the primary tumor and metastasis [23, 31].
The acquisition of secondary mutations, which is a frequent
phenomenon in many other cancer types, do not seem to play
a major role in therapy-related resistance to anti-EGFR
antibody treatment in mCRC: in fact, the evaluation of K-RAS/
BRAF status before and after anti-EGFR antibody treatment
carried out by Gattenlöhner et al. [25] is resulted highly
concordant (95% for K-RAS, 100% for BRAF). However, ∼5%
to 10% of mCRC show K-Ras molecular heterogeneity between
primary, lymph node, and distant metastases [32]. Moreover, a
recent study from Baldus et al. evaluated K-RAS, BRAF, and
PI3K gene status into the primary tumor, comparing the
tumor center and the invasion fronts. The intratumoral
heterogeneity of K-RAS, BRAF, and PIK3CA mutations was
observed in 8%, 1%, and 5% of primary tumors, respectively
[33]. According to the evidence of intratumoral heterogeneity,
the occurrence of a disease progression after the initial
response in a WT K-RAS primary tumor could not be due to a
late acquisition of the mutation rather to the progressive
prevalence of a mutated clone, caused by a sort of ‘cetuximab-
driven mutated genotype acquisition’ occurring during therapy
(Figure 2). On the basis of these results and to our knowledge,
we conducted the ﬁrst phase II prospective trial evaluating the
efﬁcacy of a cetuximab rescue in K-RAS WT mCRC patients
who experienced a clinical beneﬁt followed by a progression
with a previous cetuximab-based therapy. After the failure of
an irinotecan-based ﬁrst-line therapy, the recourse to a
cetuximab-based therapy in K-RAS WT mCRC patients, even
without modiﬁng K-RAS gene status, could lead to the
destruction of WT cells and to the prevalence of mutated
clones, which lead to a ﬁrst progression of disease. A further
line of therapy without cetuximab could restore K-RAS WT
clones, which could constitute the major part of the tumor
mass at the time of a following progression of disease. At this
point, a rescue through a cetuximab-based new line therapy
may determine a further shrinkage of the disease. Moreover,
the tumor cell entrance to epithelial-to-mesenchymal
transition (EMT) or the reverse mesenchymal-to-epithelial
transition may justify response or refractoriness, respectively,
in patients retreated with Cetuximab. EMT is characterized by
the combined loss of epithelial cell junction proteins such as
E-cadherin and the gain of mesenchymal markers such as
vimentin. Therefore, it is likely that the epithelial cells are
more susceptible to EGFR-targeted therapies due to their
activation of AKT primarily through EGFR-ErbB3.
Mesenchymal cells activate AKT through alternative pathways
like integrin-linked kinase (ILK) [34] and are largely resistant
to EGFR inhibitors. Cetuximab-based therapy could lead
during the time, after a ﬁrst response, to activation of this
alternative pathway, ILK-dependent, which allow the EMT. A
further line without anti-EGFR therapy could down-regulate
this process restoring cetuximab sensitiveness. In fact, we
observed that rechallenge with the same cetuximab-based
Figure 2. Hypothesis for the overcoming of acquired resistance to cetuximab. The tumor burden usually shows heterogeneity. So it is possible that before
treatment both cetuximab-sensitive and -resistant are present. After the initial response, disease progression occurs in a wild-type KRAS tumor. This
occurrence could be explained by the progressive prevalence of a mutated clone rather than by the late acquisition of a new mutation. This mechanism
could be deﬁned ‘cetuximab-driven mutated genotype acquisition’, which occurs during therapy.
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therapy can achieve a new important clinical beneﬁt delaying
the progression of disease and improving the therapeutic
options. The present phase II trial is the ﬁrst demonstration in
literature of a potential clinical beneﬁt deriving from a
rechallenge with cetuximab-based therapy in K-RAS WT
colorectal patients previously treated with the same anti-
EGFR-based protocol.
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